SKP.L Regulatory News (SKP)

12 Oct 2005 11:23

Skyepharma PLC12 October 2005 For Immediate Release 12 October 2005 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY ORINDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN ORNEW ZEALAND THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES.SECURITIES MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATIONOR AN EXEMPTION FROM REGISTRATION. THE SECURITIES TO BE ISSUED PURSUANT TO THERIGHTS ISSUE HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE US SECURITIESACT OF 1933 OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION OF THEUNITED STATES, AND THE SECURITIES ISSUED AS PART OF THE RIGHTS ISSUE MAY NOT BEOFFERED, SOLD, DELIVERED, RENOUNCED OR TRANSFERRED, DIRECTLY OR INDIRECTLY, INTHE UNITED STATES OR TO US PERSONS (SUBJECT TO CERTAIN EXCEPTIONS). SKYEPHARMA PLC Filing of Prospectus Pursuant to the Rights Issue announced on 28 September 2005, SkyePharma PLC (the"Company") announces that it has today filed the Prospectus with the FinancialServices Authority in accordance with the Prospectus Rules. Expected timetable of principal events Record Date for the Rights Issue 7 October 2005Dealings in the New Ordinary Shares, nil paid, commence 13 October 2005Latest time and date for acceptance and payment in full 11am on 2 November 2005 Two copies of the Prospectus have been submitted to the Financial ServicesAuthority and will be available shortly for inspection at the Financial ServicesAuthority's Document Viewing Facility which is situated at: Financial ServicesAuthority, 25 The North Colonnade, Canary Wharf, London, E14 5HS (Tel: 020 70661000). The Prospectus has also been made available to the public pursuant to section3.2 of the Prospectus Rules and copies of the Prospectus will be available from,or can be inspected at, the offices of Stringer Saul LLP, 17 Hanover Square,London W15 1HU and the registered office of the Company at 105 Piccadilly,London W1J 7NJ. Definitions used in the Prospectus shall have the same meanings when used inthis announcement, unless the context requires otherwise. For further information, please contact: Skyepharma 020 7491 1777Michael Ashton (Chief Executive Officer)Donald Nicholson (Finance Director)Peter Laing (Director of Corporate Communications) Credit Suisse First Boston (Europe) Limited 020 7888 8888Paul Nicholls/Andrew Christie/Stephanie Leouzon Buchanan Communications 020 7466 5000Tim Anderson/ Mark Court/ Rebecca Skye Dietrich THIS ANNOUNCEMENT IS NOT A PROSPECTUS BUT IS AN ADVERTISEMENT FOR THE PURPOSESOF THE PROSPECTUS RULES OF THE FINANCIAL SERVICES AUTHORITY. NO OFFER,INVITATION OR INDUCEMENT TO ACQUIRE NEW ORDINARY SHARES, PROVISIONAL ALLOTMENTLETTERS, NIL PAID RIGHTS, FULLY PAID RIGHTS OR ANY OTHER SECURITIES IN THECOMPANY IS BEING MADE BY OR IN CONNECTION WITH THIS ANNOUNCEMENT. ANY OFFER,INDUCEMENT OR ANNOUNCEMENT TO ACQUIRE NEW ORDINARY SHARES, PROVISIONAL ALLOTMENTLETTERS, NIL PAID RIGHTS, FULLY PAID RIGHTS OR ANY OTHER SECURITIES IN THECOMPANY WILL BE MADE SOLELY BY MEANS OF THE PROSPECTUS, PUBLISHED TODAY, ASUPDATED BY ANY SUPPLEMENTARY PROSPECTUS, AND ANY DECISION TO KEEP, BUY OR SELLSHARES IN THE COMPANY SHOULD BE MADE SOLELY ON THE BASIS OF THE INFORMATIONCONTAINED IN SUCH DOCUMENT(S). Credit Suisse First Boston (Europe) Limited, which is regulated in the UnitedKingdom by the Financial Services Authority, is acting exclusively for theCompany and for no-one else in connection with the Rights Issue and listing ofthe New Ordinary Shares on the Official List and their admission to trading onthe London Stock Exchange's market for listed securities and will not beresponsible to anyone other than the Company for providing the protectionsafforded to customers of Credit Suisse First Boston (Europe) Limited or forproviding advice in relation to the Rights Issue, proposed listing or admissionto trading, the contents of this announcement or any other matter referred toherein. This information is provided by RNS The company news service from the London Stock Exchange